BioAtla Faces Nasdaq Review of Continued Listing Status

An announcement from BioAtla ( (BCAB) ) is now available.

On February 8, 2026, BioAtla disclosed that Nasdaq’s Listing and Hearing Review Council had called for review a February 6, 2026 decision to suspend trading in, and ultimately delist, the company’s securities from Nasdaq, and that the Council stayed any suspension or delisting during this review. As a result, BioAtla’s common stock will continue trading while the review, expected to take weeks to a few months, examines Nasdaq’s earlier determination that the company failed to meet minimum bid price and stockholders’ equity requirements, a process that introduces uncertainty for shareholders over the company’s long‑term Nasdaq listing status.

The most recent analyst rating on (BCAB) stock is a Hold with a $0.18 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.

Spark’s Take on BCAB Stock

According to Spark, TipRanks’ AI Analyst, BCAB is a Neutral.

The score is held down primarily by weak financial fundamentals (no TTM revenue, large losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative momentum). Offsetting support comes from more constructive clinical/regulatory progress and potential partnering/financing developments, but near-term liquidity and listing/compliance risks remain key overhangs.

To see Spark’s full report on BCAB stock, click here.

More about BioAtla

BioAtla, Inc. is a biopharmaceutical company whose common stock is listed on the Nasdaq Capital Market. The company’s securities are subject to Nasdaq’s continued listing standards, including minimum bid price and stockholders’ equity requirements that govern its ongoing eligibility to trade on the exchange.

Average Trading Volume: 2,430,491

Technical Sentiment Signal: Sell

Current Market Cap: $13.49M

Learn more about BCAB stock on TipRanks’ Stock Analysis page.